Invikafusp Alfa Receives FDA Fast Track Designation for TMB-High CRC
Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.
Related Articles
JNCCN 360 – Breast – Justin M. Balko, PharmD, PhD, on Chemotherapy Plus Immunotherapy for Early-Stage Triple-Negative Breast Cancer
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
Rathmell steps down at NCI as Trump team considers candidates to replace her Wafik El-Deiry, Harvey Risch have been interviewed – The Cancer Letter
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and…
Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care
Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Abstracts
Submit an abstract to the AACR IO 2025, February 23-26, 2025, in Los Angeles. This new major conference will encompass the very best of basic,…
Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis
Key PointsFunction of antifibrinolytic protein α2AP can be modulated using Affimers, facilitating lysis of clots from plasma and whole blood samples.α2AP-s
Jennifer Woyach named director of OSUCCC—James’s Division of Hematology – The Cancer Letter
Jennifer A. Woyach, a blood cancer doctor and researcher who has been with Ohio State for more than 12 years, was named director of the…
Elinzanetant Shows VMS Reduction in Women With or at High Risk of HR+ Breast Cancer
Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in the OASIS 4 trial.
Everolimus/Lanreotide Prolongs PFS in Unresectable/Recurrent GEP-NETs
Everolimus plus lanreotide elicited a PFS of 29.7 months compared with 11.5 months from everolimus monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.
